

Table S1. Propensity score-matched patients' cohort (n=810).

Covariates	Levels	Group		p-value
		Surgery Performed (n=405)	Recommended but refused (n=405)	
Age at diagnosis*		65.9±14.5, 65 (56,77)	65.6±14.2, 65 (57,77)	0.75
Year of diagnosis	2010	91 (22.2%)	91 (22.5%)	0.98
	2011	79 (19.5%)	75 (18.5%)	
	2012	58 (14.3%)	61 (15.1%)	
	2013	68 (16.8%)	62 (15.3%)	
	2014	46 (11.4%)	52 (12.8%)	
	2015	64 (15.8%)	64 (15.8%)	
Race	white	308 (76.1%)	305 (75.3%)	0.98
	black	63 (15.6%)	64 (15.8%)	
	other race	33 (8.2%)	35 (8.6%)	
	Unknown	1 (0.3%)	1 (0.3%)	
T stage	T0	6 (1.5%)	5 (1.2%)	0.89
	T1	36 (8.9%)	27 (6.7%)	
	T2	100 (24.7%)	100 (24.7%)	
	T3	56 (13.8%)	57 (14.1%)	
	T4	139 (34.3%)	148 (36.5%)	
	TX	68 (16.8%)	68 (16.8%)	
N stage	N0	117 (28.9%)	112 (27.7%)	0.31
	N1	180 (44.4%)	165 (40.7%)	
	N2	28 (6.9%)	44 (10.9%)	
	N3	47 (11.6%)	44 (10.9%)	
	NX	33 (8.2%)	40 (9.9%)	
Metastasis site	Distant lymphnode mets only	47 (11.6%)	45 (11.1%)	0.47
	Bone Mets only	145 (35.8%)	136 (33.6%)	
	Visceral Mets only (One organ)	90 (22.2%)	95 (23.5%)	
	Bone + Visceral Mets (One organ)	71 (17.5%)	71 (17.5%)	
	Visceral Mets (≥2 organs) w/o Bone Mets	52 (12.8%)	58 (14.3%)	
Number of Met sites	0	47 (11.6%)	45 (11.1%)	0.93
	1	235 (58.0%)	231 (57.0%)	
	2	89 (22.0%)	88 (21.7%)	
	3	29 (7.2%)	36 (8.9%)	
	4	5 (1.2%)	5 (1.2%)	
Her2/HR status	HR+/HER2-	199 (49.1%)	195 (48.2%)	0.94
	HR+/HER2+	63 (15.6%)	57 (14.1%)	
	HR-/HER2+	31 (7.7%)	31 (7.7%)	
	TRIPLE NEGATIVE	39 (9.6%)	43 (10.6%)	
	Unknown	73 (18.0%)	79 (19.5%)	
Her2	Negative	240 (59.3%)	238 (58.8%)	0.72
	Positive	94 (23.2%)	90 (22.2%)	
	Borderline	12 (3.0%)	12 (3.0%)	
	Unknown	59 (14.6%)	65 (16.1%)	
ER	Negative	76 (18.8%)	82 (20.3%)	0.52
	Positive	287 (70.9%)	272 (67.2%)	
	Borderline	0 (0.0%)	1 (0.3%)	
	Unknown	42 (10.4%)	50 (12.4%)	
PR	Negative	127 (31.4%)	131 (32.4%)	0.37
	Positive	234 (57.8%)	219 (54.1%)	
	Borderline	0 (0.0%)	2 (0.5%)	
	Unknown	44 (10.9%)	53 (13.1%)	